Wednesday, July 8, 2026

Patent intelligence · US

US 12030863

Prodrugs of urolithins and uses thereof

granted A61KA61K31/366A61K31/4025A61K45/06
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 18
Applicant portfolio 60
Patent details — US 12030863
Jurisdiction
US
Status
granted
Grant date
Jul 9, 2024
Expiration
Jul 4, 2044
Applicant
Amazentis SA
Claims
10
CPC classes
A61K, A61K31/366, A61K31/4025, A61K45/06
View on Google Patents ↗

Quick answer

US 12030863 (Prodrugs of urolithins and uses thereof) is held by Amazentis SA. Status: granted. Granted Jul 9, 2024. Expires Jul 4, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
Amazentis SA
Grant date
Expiration
Claims
10
CPC classes
A61K, A61K31/366, A61K31/4025, A61K45/06, A61P, A61P3/00

More from Amazentis SA

Related pharmaceutical patents in our USPTO index.

  1. US 12310943

    Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

    Amazentis SA · Expires May 22, 2045

    granted
  2. US 12297182

    Compositions comprising an urolithin compound

    Amazentis SA · Expires May 8, 2045

    granted
  3. US 12226455

    Medical composition for treating cardiac wasting and cachexia

    RELAXERA PHARMAZEUTISCHE GMBH & CO. KG · Expires Feb 13, 2045

    granted
  4. US 12220424

    Compositions comprising nicotinamide riboside and a urolithin

    Amazentis SA · Expires Feb 6, 2045

    granted
  5. US 12109190

    Urolithins as immune response enhancers

    Amazentis SA · Expires Oct 3, 2044

    granted
  6. US 12036205

    Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

    Amazentis SA · Expires Jul 11, 2044

    granted
  7. US 11969408

    Method for improving mitophagy in subjects

    Amazentis SA · Expires Apr 25, 2044

    granted

Frequently asked questions

What is US patent 12030863?

US 12030863 (Prodrugs of urolithins and uses thereof) is held by Amazentis SA. Status: granted. Granted Jul 9, 2024. Expires Jul 4, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12030863?

Amazentis SA is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 60 pharmaceutical patents for this assignee.

When does US 12030863 expire?

Our index shows an expiration date of Jul 4, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.